{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-019321","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2026-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.972231+00:00","generated_at":"2026-05-16T01:12:01.651903+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"INmune Bio receives FDA alignment to advance XPro1595 to registrational study in Alzheimer's","bullets":["FDA End-of-Phase 2 meeting yielded alignment to proceed with registrational study in biomarker-enriched early Alzheimer's patients.","Phase 2 MINDFuL trial results and FDA feedback to be detailed in a webinar on Feb 27, 2026 at 9:30 AM ET.","Company will seek a global partnership to maximize XPro1595's clinical and commercial potential.","Key opinion leaders Dr. Michael Woodward and Dr. Sharon Cohen to present MINDFuL trial data and discuss pathway."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-019321","json":"https://secwatch.observer/filing/0001213900-26-019321.json","markdown":"https://secwatch.observer/filing/0001213900-26-019321.md","text":"https://secwatch.observer/filing/0001213900-26-019321.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026019321/0001213900-26-019321-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026019321/ea0277934-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:12:01.651903+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}